Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.04 by 250 percent. This is a 166.67 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $9.300 million which missed the analyst consensus estimate of $16.918 million by 45.03 percent. This is a 48.95 percent decrease over sales of $18.218 million the same period last year.